Ladenburg Thalmann Financial Services set a $90.00 price objective on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research note issued to investors on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
ALNY has been the topic of several other research reports. Credit Suisse Group reaffirmed a hold rating and issued a $50.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 9th. Chardan Capital set a $110.00 price target on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a research report on Monday, June 12th. ValuEngine raised shares of Alnylam Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, June 13th. FBR & Co reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a research report on Monday, March 20th. Finally, J P Morgan Chase & Co reaffirmed a hold rating on shares of Alnylam Pharmaceuticals in a research report on Monday, June 26th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $78.83.
Shares of Alnylam Pharmaceuticals (ALNY) opened at 80.51 on Monday. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $86.92. The company has a 50 day moving average price of $78.15 and a 200-day moving average price of $57.51. The firm’s market cap is $6.94 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. The business had revenue of $19 million during the quarter, compared to the consensus estimate of $22.91 million. During the same period in the previous year, the business posted ($1.21) EPS. Alnylam Pharmaceuticals’s revenue was up 160.3% compared to the same quarter last year. On average, analysts expect that Alnylam Pharmaceuticals will post ($5.24) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by BNB Daily and is owned by of BNB Daily. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/07/21/alnylam-pharmaceuticals-inc-nasdaqalny-pt-set-at-90-00-by-ladenburg-thalmann-financial-services.html.
In other news, SVP Akshay Vaishnaw sold 43,750 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $65.00, for a total transaction of $2,843,750.00. Following the completion of the sale, the senior vice president now owns 43,047 shares in the company, valued at approximately $2,798,055. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Laurie Keating purchased 11,500 shares of the firm’s stock in a transaction dated Tuesday, May 30th. The shares were bought at an average price of $65.35 per share, with a total value of $751,525.00. Following the purchase, the senior vice president now owns 11,500 shares in the company, valued at $751,525. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 64,125 shares of company stock valued at $4,325,000. 4.30% of the stock is currently owned by company insiders.
Several large investors have recently modified their holdings of ALNY. Dodge & Cox bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $344,633,000. BlackRock Inc. raised its stake in shares of Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares during the last quarter. Perceptive Advisors LLC raised its position in Alnylam Pharmaceuticals by 831.4% in the first quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock worth $56,553,000 after buying an additional 985,000 shares in the last quarter. Norges Bank acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $24,885,000. Finally, Rockefeller Financial Services Inc. raised its position in Alnylam Pharmaceuticals by 4,724.4% in the first quarter. Rockefeller Financial Services Inc. now owns 506,223 shares of the biopharmaceutical company’s stock worth $25,944,000 after buying an additional 495,730 shares in the last quarter. Institutional investors own 89.22% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.